Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate

Samuel A. Jacobs, Nicholas Vidnovic, Hitendra Patel, Lorinda A. Soma, Yuan Chang, Noah Bass, Steven H. Swerdlow

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Multicentric Castleman disease (MCD) is a nonneoplastic lymphoproliferative disorder that has a poor prognosis. Optimal treatment is unknown. There are a few reported cases of MCD and rheumatoid arthritis. In this study, we report a patient with rheumatoid arthritis diagnosed with Kaposi's sarcoma herpesvirus-(KSHV, human herpesvirus-8) associated MCD that showed expression of viral IL-6. Treatment with methotrexate (MTX) resulted in a complete remission of her disease lasting for 54+ months. Multiple studies have suggested that MCD and rheumatoid arthritis are associated with overexpression of the growth-promoting cytokine interleukin-6 (IL-6), and that MTX downregulates the production of this cytokine in vivo. As such, we suggest that the dramatic improvement in this patient's disease is due to the immunomodulatory properties of MTX.

Original languageEnglish (US)
Pages (from-to)1148-1150
Number of pages3
JournalClinical Rheumatology
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2007

Keywords

  • Castleman disease
  • Interleukin-6
  • Methotrexate

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate'. Together they form a unique fingerprint.

  • Cite this